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ORIGINAL ARTICLE

MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is
downregulated in human bladder and breast cancer
A Vecchione1,5,8, M Fassan1,6,8, V Anesti2, A Morrione1, S Goldoni3, G Baldassarre4, D Byrne1,
D D’Arca1, JP Palazzo3, J Lloyd3, L Scorrano2, LG Gomella1, RV Iozzo3 and R Baffa1,7
1
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA; 2Dulbecco-Telethon Institute,
Venetian Institute of Molecular Medicine, Padova, Italy; 3Department of Pathology, Anatomy and Cell Biology, Kimmel Cancer
Center, Thomas Jefferson University, Philadelphia, PA, USA and 4Division of Experimental Oncology 2, CRO-IRCCS, Aviano, Italy

Allelic deletions on human chromosome 12q24 are
frequently reported in a variety of malignant neoplasms,
indicating the presence of a tumor suppressor gene(s) in
this chromosomal region. However, no reasonable candidate has been identiﬁed so far. In this study, we report the
cloning and functional characterization of a novel
mitochondrial protein with tumor suppressor activity,
henceforth designated MITOSTATIN. Human MITOSTATIN was found within a 3.2-kb transcript, which
encoded a B62 kDa, ubiquitously expressed protein with
little homology to any known protein. We found homozygous deletions and mutations of MITOSTATIN gene in
B5 and B11% of various cancer-derived cells and solid
tumors, respectively. When transiently overexpressed,
MITOSTATIN inhibited colony formation, tumor cell
growth and was proapoptotic, all features shared by
established tumor suppressor genes. We discovered a
speciﬁc link between MITOSTATIN overexpression and
downregulation of Hsp27. Conversely, MITOSTATIN
knockdown cells showed an increase in cell growth and cell
survival rates. Finally, MITOSTATIN expression was
signiﬁcantly reduced in primary bladder and breast
tumors, and its reduction was associated with advanced
tumor stages. Our ﬁndings support the hypothesis that
MITOSTATIN has many hallmarks of a classical tumor
suppressor in solid tumors and may play an important role
in cancer development and progression.
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published online 20 October 2008
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Introduction
During the course of cancer development, a normal cell
progresses towards malignancy by acquiring a speciﬁc
series of mutations (Hanahan and Weinberg, 2000).
Over the past decades, genetic studies have demonstrated that cancer cells accumulate DNA changes that
activate oncogenes and inactivate tumor suppressor
genes. The role of tumor suppressor genes in neoplastic
development is crucial, given that reintroduction of one
or more of these genes into cells in which their function
is compromised can completely revert the neoplastic
phenotype. Therefore, it is not surprising that several
tumors show a high frequency of loss of heterozygosity
(LOH) at speciﬁc chromosomal regions encompassing
tumor suppressor genes. LOH in the telomeric regions
of chromosome 12 has been observed in many solid
tumors, such as breast (Tirkkonen et al., 1997; Aubele
et al., 2000), lung (Shiseki et al., 1996), gastric, and
prostate cancers (Schmutte et al., 1997; Sattler et al.,
1999), pancreatic adenocarcinoma (Kimura et al., 1998),
head and neck squamous cell carcinoma (Field et al.,
1995), distal bile duct carcinoma (Rijken et al., 1999),
renal cell carcinomas (Jiang et al., 1998) and urothelial
carcinoma of the urinary bladder (Koo et al., 1999).
These observations support the concept that cloning and
characterization of tumor suppressor genes may lead to
the development of novel therapies for malignant tumors.
In the process of screening for genes expressed during
growth arrest induced by the small leucine-rich proteoglycan decorin (Santra et al., 1995, 1997; Moscatello
et al., 1998; Csordas et al., 2000; Xu et al., 2002;
Goldoni et al., 2007), we identiﬁed an expressedsequence-tag that was upregulated in three different
growth-suppressed tumor cell lines (that is, decorintransfected tumor cells). We investigated in more detail
the nature of one of these expressed-sequence-tags for
several reasons. First, its key chromosomal location is a
known fragile site in cancer. Second, the overexpression
of this gene product was induced by decorin, a growthinhibitory protein (Santra et al., 1997; Goldoni et al.,
2007). Third, it is well established that the regulatory
effect on cell growth may be mediated by variations on
the level of expression of downstream genes through a
paracrine or autocrine mechanism.
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In this study, we described the cloning of a novel
putative tumor suppressor gene (previously identiﬁed as
Ts12q for tumor suppressor at 12q) and named it
MITOSTATIN, for mitochondrial protein with oncostatic activity. Our genetic and functional studies
support a potential key role for MITOSTATIN in the
development and progression of cancer.

Results
Cloning and characterization of MITOSTATIN
Using differential hybridization of cDNA libraries
(subtractive hybridization) with probes obtained from
logarithmically growing or growth-suppressed cells (that
is, decorin-transfected tumor cells), we isolated different
growth-regulated genes. Northern blot of one of these
novel transcripts showed a 10-fold induction in three
different decorin-transfected cells (A431, HeLa and
HT1080 cells), recognizing a transcript of B3.2 kb (data
not shown). The difference in the MITOSTATIN
protein levels between the clone and the parental line
was conﬁrmed by immunoblotting analysis (Supplementary Figure S1). At the time of the cloning, homology
searches against expressed-sequence-tag databases
showed complete identity with a published human
expressed-sequence-tag. Human testis and skeletal
muscle cDNA libraries were screened and 30 /50 RACE
PCR was performed to clone the 3.2-kb full-length
cDNA, including a 1497 bp open reading frame containing a starting ATG codon at position 216 within a
perfect Kozak consensus sequence that we called
MITOSTATIN (deposited in the GeneBank with
accession number AY007230). The entire human
MITOSTATIN spans 17 kb of genomic DNA, with 13
exons, 12 of which were coding exons (Figure 1a).
Search analysis against available protein databases
identiﬁed Pan troglodytes, Pongo Pygmaeus, Canis
familiaris, Bos Taurus, Mus musculus and Rattus
norvegicus proteins with high homology (>80%) with
the MITOSTATIN ORF, indicating that it is highly
conserved in mammals (Figure 1b and Supplementary
Figure S2).
Expression of human MITOSTATIN
MITOSTATIN expression in normal human tissues was
examined using two multiple normal-tissue northern
blots. All tissues examined (brain, heart, skeletal muscle,
colon, thymus, spleen, kidney, liver, small intestine,
placenta, lung, peripheral blood leukocyte, prostate,
testis and ovary) demonstrated the presence of the 3.2 kb
MITOSTATIN transcript, albeit at different levels. The
highest RNA expression was detected in heart, skeletal
muscle, kidney, liver and testis. A larger 5.5 kb
transcript was observed in heart and skeletal muscle.
A smaller RNA transcript of 1.24 kb was also detected
in heart mRNA (Figure 1c).
To determine whether the wild-type MITOSTATIN
cDNA could be translated in vitro, we performed in vitro
transcription/translation by a TnT-coupled reticulocyte
Oncogene

Figure 1 MITOSTATIN gene structure, homologies and expression in normal human tissues. (a) Schematic representation of the
MITOSTATIN gene and distribution of primers along the
MITOSTATIN transcript. Also the four point mutations detected
in cancer cells are shown. Primer sets used in the RT–PCR study
are numbered underneath. (b) Phylogenetic tree among different
species of MITOSTATIN orthologs. (c) MITOSTATIN is ubiquitously expressed in normal human tissues as shown by northern
blot analysis on normal human tissue samples (1 ¼ brain, 2 ¼ heart,
3 ¼ skeletal muscle, 4 ¼ colon, 5 ¼ thymus, 6 ¼ spleen, 7 ¼ kidney,
8 ¼ liver,
9 ¼ small
intestine,
10 ¼ placenta,
11 ¼ lung,
12 ¼ peripheral blood leukocyte, 13 ¼ prostate, 14 ¼ testis and
15 ¼ ovary). The b-actin RNA was used as control.

system. Analysis of the synthesized protein by
SDS–polyacrylamide gel electrophoresis and autoradiography conﬁrmed the 61.2 kDa predicted protein
(Supplementary Figure S4). To assess whether MITOSTATIN cDNA could be translated in vivo, full-length
MITOSTATIN was cloned in pcDNA3.1 Myc/His
vector. Western blot analysis of the fusion protein in
HeLa and 293T transfected cells showed presence of the
MITOSTATIN protein around 62 kDa.
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Next, we determined the subcellular localization of
this newly identiﬁed gene product to gain insights into
its function. Various expression vectors harboring
MITOSTATIN with green ﬂuorescent protein (GFP)
located at the N- or C-terminal ends, or with FLAG
epitopes at the C terminus were generated and tested in
transient cell transfection assays in HeLa cells. In all
cases, MITOSTATIN exhibited punctuate vesicular
distribution throughout the cytoplasm (Figure 2a).
Next, we discovered that MITOSTATIN colocalized
with mitochondrial markers (Figure 2b). To corroborate
this subcellular distribution, we used subcellular fractionation and immunoblotting of the various fractions.
The results showed that MITOSTATIN speciﬁcally
sedimented in the heavy mitochondrial fraction together
with cytochrome c (Figure 2c). Similar results were
obtained in embryonic kidney 293T cells and prostate
cancer-derived cell lines PC3 and LNCaP (Supplemen-

tary Figure S5). We did not detect any colocalization of
MITOSTATIN with lysosomes, Golgi apparatus or
endosomal compartment (Supplementary Figure S6).
These results clearly show that MITOSTATIN is a
novel mitochondria-associated protein.
MITOSTATIN interferes on mitochondria morphology
and ultrastructural organization
As confocal images of subcellular localization suggested
that MITOSTATIN protein is localized at the mitochondrial level, we analysed MITOSTATIN effect on
normal mitochondrial morphology. Mitochondrial
shape results from the balance between fusion and
ﬁssion, regulated by a family of ‘mitochondria-shaping’
proteins impinging on both sides of the equilibrium.
Core components in mammals include the profusion
proteins optic atrophy 1, mitofusins 1 and 2; and the

Figure 2 Subcellular localization of MITOSTATIN. (a) MITOSTATIN cDNAs fused with pEGFP-N2, pEGFP-C1 and FLAG
exhibited punctuate vesicular distribution through the cytoplasm when transfected in HeLa cells. Bars, 20 mm. (b) Confocal images in
HeLa cells of MITOSTATIN-GFP chimeric protein and mitochondrially targeted dsRED (mtRFP); merged image shows a partial
colocalization (yellow). Bar, 10 mm. (c) Western blot analysis using anti-FLAG antibody in HeLa cells revealed the presence of
B62 kDa band in the mitochondrial pellet fraction of the transfected (HM, heavy membranes; LM, light membranes; C, cytoplasm; N,
nucleus). Antibodies speciﬁc for cytochrome c (mitochondrial marker), caspase-3 (cytosolic marker) and PARP (nuclear marker) were
used to characterize the fractions.
Oncogene
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proﬁssion ones Fis1 and dynamin-related protein 1
(Drp1) (Cereghetti and Scorrano, 2006). We wished to
verify if high levels of MITOSTATIN were associated
with changes in normal mitochondrial morphology. To
this end we expressed a mitostatin-V5 fusion protein
together with the ﬂuorescent protein dsRED targeted to
the mitochondrial matrix (mt-dsRED) (Dimmer et al.,
2008) and acquired confocal images of the mitochondrial reticulum in HeLa cells (Figures 3a–d). The high
levels of MITOSTATIN induced marked changes in
mitochondrial morphology, including fragmentation of
the highly branched network of HeLa cells and
clumping of the fragmented organelles in the perinuclear
region. As mitochondrial fragmentation can depend on
the activation of the core ﬁssion machinery, we tested if
a dominant negative mutant of Drp1 could interfere
with the observed changes. The dominant negative
Drp1K38A (Smirnova et al., 1998) further elongated the
mitochondrial network of HeLa cells and it blocked
fragmentation induced by MITOSTATIN, as further
conﬁrmed by a morphometric analysis (Figure 3e).
However, Drp1K38A had no effect on perinuclear
clusterization of mitochondria observed in cells expressing high levels of MITOSTATIN, suggesting that the
two observed phenotypes can be functionally dissected.
Of note, as these experiments were carried in the
presence of the broad caspase inhibitor zVAD-fmk, it
is unlikely that the observed changes reﬂect the
activation by MITOSTATIN of the apoptotic cascade,
often associated with mitochondrial fragmentation and
clustering. In conclusion, fragmentation induced by
MITOSTATIN depends on the core mitochondrial
ﬁssion machinery, while it can induce perinuclear

clustering of the organelle that occurs when ﬁssion is
blocked.
To further investigate MITOSTATIN’s relationship
with mitochondria, we analysed wild-type PC3 prostate
carcinoma-derived cells and PC3 MITOSTATIN-overexpressing clones (PC3 B2) by transmission electron
microscopy. Ultrastructural analysis of MITOSTATINoverexpressing PC3 cells revealed that the mitochondria
were often round and showed abnormal christae in
contrast to the wild-type cells (Figure 4a). In addition,
mitochondria were often swollen and lost some of their
christae and matrix material (Figures 4b and c).
De novo expression of MITOSTATIN inhibits cell
growth
We hypothesized that MITOSTATIN could be linked to
growth control insofar as it was a decorin-induced gene.
Therefore, we utilized the MITOSTATIN-GFP constructs described above to test their biological activity in
transformed cells. MITOSTATIN expression signiﬁcantly affected HeLa colony formation, with a drastic
reduction (65%) in the number and size of colonies as
compared to vector-transfect controls (Figure 5a,
Po0.05, n ¼ 3). Confocal microscope analysis demonstrated that the MITOSTATIN-GFP colonies were
indeed derived from cells not expressing MITOSTATIN,
as shown by absence of green ﬂuorescence (Figure 5b).
Comparably, the rate of DNA synthesis in HeLa and
293T cells decreased by 83 and 60%, respectively
(Figures 5c–d, Po0.01).
To further investigate the MITOSTATIN effects on
tumor cell growth, we transfected PC3, LNCaP and

Figure 3 MITOSTATIN promotes mitochondrial fragmentation and clumping independently of Drp1. (a–d) Representative confocal
images of mt-dsRED ﬂuorescence in HeLa cells transfected with mt-dsRED (a) or co-transfected with mt-dsRED and MITOSTATIN
(b), dominant-negative Drp1 (Drp1K38A) (c) and MITOSTATIN plus Drp1K38A (d). Bar, 10 mm. (e) morphometric analysis of
mitochondrial fragmentation induced by overexpression of MITOSTATIN. Data represent mean±s.e. of ﬁve independent
experiments.
Oncogene
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5637 cells with a MITOSTATIN-V5 fusion expression
construct, and PC3 and DU145 cells with an antisense
cDNA construct. Moreover, we placed MITOSTATIN
in a self-inactivating retroviral vector under the control

of an inducible Drosophila HSP70 promoter, which we
used to transfect DU145 cells. We obtained ﬁve clones
stably overexpressing MITOSTATIN and two clones
which showed a decreased level of endogenous MITOSTATIN (Figures 6a and b). Clones showed different
levels of the protein overexpression: in PC3 cells, PC3
B2 had a 2.0-fold increase over parental cells; DU145MITOSTATIN showed a 4.2-fold increase; in LNCaP
clones, LNCaP B1A, LNCaP B3A and LNCaP A3A
had a 1.6-, 2.1- and 2.6-fold increase, respectively; 5637
B3 MITOSTATIN expression was 2.9 times over the
parental cells expression.
As observed in transiently transfected clones, MITOSTATIN overexpressing clones showed a statistically
signiﬁcant reduction in cell number when compared
with control vector and parental cells after 72 h
(Figure 6c, n ¼ 3). Antisense clones PC3 M2 and
DU145 M2 did not show a statistically signiﬁcant
growth increase in comparison to control cells (P ¼ NS,
n ¼ 3).
A link between MITOSTATIN, Hsp27 expression and
apoptosis
Next, we determined whether MITOSTATIN would
affect apoptosis. To this end, we treated various tumor
cell lines with staurosporine (1 mM for 4 h), an established inducer of apoptosis (Mehlen et al., 1996).
Because several mitogen-activated protein kinases are
involved in the control of the apoptotic process, we
tested the activation of several proteins in the Akt and
Jnk kinase pathways after induction of apoptosis by
staurosporine treatment (data not shown). We discovered that the phosphorylation of Hsp27 at Ser82 was
speciﬁcally and uniquely inhibited by MITOSTATIN
overexpression (Figure 7c). Moreover, Hsp27 levels
were inversely proportional to the levels of MITOSTATIN expression in prostate cancer cell lines (Figures 6b
and 7c). Remarkably, Hsp27 decreased in LNCaP B1A,
B3A and A3A MITOSTATIN overexpressing clones,
and its level was higher than in the parental cells when
MITOSTATIN expression was abrogated with antisense
mRNA in clones PC3 M2 and DU145 M2 (Figure 6b).
In all cases, the MITOSTATIN-overexpressing cells
showed a signiﬁcant increase in apoptotic rate as
compared to the low expressors (Figure 7a, Po0.05,
n ¼ 3). The enhanced proapoptotic activity of MITOSTATIN-overexpressing clones was further conﬁrmed by
ﬂuorescence-activated cell sorting analysis (Figure 7b).
Notably, MITOSTATIN overexpression caused an
enhanced inhibition of Hsp27-PSer82 and Hsp27-PSer78
(Figure 7c). A similar effect on Hsp27 phosphorylation
Figure 4 Ultrastructural analysis of MITOSTATIN-expressing
PC3 prostate carcinoma cells show abnormal mitochondrial
structure. (a) Electron micrograph of a wild-type PC3 cell shows
normal appearing mitochondria (empty arrows). Bar, 2 mm. (b)
Ultrastructural analysis of a MITOSTATIN-expressing cells. Note
the large number of small, swollen mitochondria (black arrows).
Bar, 2 mm. (c) High magniﬁcation of the inset in (b) shows loss of
mitochondrial matrix (asterisks) and abnormal christae (empty
arrows). Bar, 0.2 mm.
Oncogene
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Figure 5 MITOSTATIN expression affects colony formation in HeLa cells and DNA syntesis in HeLa and 293 cell lines. (a) Fortyeight hours after transfection, MITOSTATIN expression signiﬁcantly affects colony formation, with a drastic reduction (65%) in the
number and size of colonies, compared to vector only-transfect controls. (b) Confocal microscope analysis showed that the
MITOSTATIN-GFP colonies were indeed derived from cells not expressing MITOSTATIN, as shown by absence of green
ﬂuorescence. (c–d) DNA synthesis was analysed by BrdU incorporation in HeLa and 293 cell lines using two different constructs with
green ﬂuorescent protein (GFP) located at the N- or C-terminal ends. (c) Determination of BrdU incorporation showing a considerable
reduction in the rate of DNA synthesis in cells transfected with MITOSTATIN, when compared with cells transfected with the vector
alone in which we observed a reduction of 8.5%. Bars, 10 mm.

was also observed after treatments with H2O2, tumor
necrosis factor-a and actinomycin D, three established
inducers of apoptosis, in LNCaP and PC3 cell lines
(data not showed). Collectively, our ﬁndings indicate
that MITOSTATIN is involved in facilitating cancer
cells death upon apoptotic stimuli.
MITOSTATIN is mutated in various transformed cell
lines and its expression can be lost in tumor samples
To determine whether MITOSTATIN is mutated or lost
in malignant human tumors, we performed a systematic
analysis of cancer-derived cell lines and solid tumors
using reverse transcription–PCR. MITOSTATIN
mRNA was absent in B6% of the cancer samples
(one vulva, two colon and three prostate cancers; 4.2%
including the cancer cell lines). Also in the three prostate
samples, we studied the normal counterpart in which the
gene was normally expressed (Figure 8a). Four point
mutations were detected (Supplementary Figure S8). In
the gastric carcinoma-derived RF48 cell line, T345 in
exon 2 was substituted in heterozygosity by a C,
changing the amino acid from a serine to a proline
(S44P). In the prostate-derived LNCaP cell line, C 184
in exon 9 was substituted in heterozygosity by a T,
without amino acid changes (A323A). In the pancreatic
carcinoma-derived SU86 cell line, G 890 in exon 6 was
substituted in heterozygosity by an A, without changing
the glutamic acid (E225E). In the CAPAN1 pancreatic
carcinoma-derived cells, C 492 in exon 3 was homoOncogene

zygously mutated to A, changing the amino acid from
glutamic acid to lysine (E93K). Notably, all these
mutations affected amino-acid residues that are highly
conserved in evolution (Figure 1c and Supplementary
Figure S8). In immunoﬂuorence confocal analysis,
MITOSTATIN still showed a punctuate pattern of
distribution and colocalized within mitochondria in
LNCaP (Supplementary Figure S5), CAPAN and Su86.
Reduced MITOSTATIN expression in advanced bladder
and breast carcinomas
To further conﬁrm our hypothesis on the tumor
suppressive nature of MITOSTATIN, we evaluated its
expression in a series of bladder and breast cancers by
immunohistochemistry. In normal samples, high MITOSTATIN levels were detected in normal urothelial
and breast epithelial cells (Figures 8b and c, Supplementary Figure S9). Also, as expected from the RNA
analysis (Figure 1), MITOSTATIN protein was readily
detected in smooth muscle and endothelial cells
(Figure 8b). MITOSTATIN was mainly localized into
the cytoplasm, in agreement with the mitochondrial
nature detected by transient expression. Interestingly, in
normal mammary glands a strong MITOSTATIN
signal was detected in both cytoplasm and cell membrane. In contrast, 22% (10 of 45) of bladder cancers did
not show any MITOSTATIN expression. Univariate
analysis revealed a decreased MITOSTATIN immunohistochemical score associated with advanced tumor
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Figure 6 MITOSTATIN inhibits cell growth in bladder and prostate cancer cells by a downregulation of Hsp27. Endogenous and
ectopic MITOSTATIN protein is detected in prostate (a) and bladder (b, left panel) stable MITOSTATIN-transfectant cells. (b) A
signiﬁcant reduction of MITOSTATIN protein is detected in PC3 M2 and DU145 M2 cells stably transfected with a MITOSTATIN
antisense-vector. Reduced Hsp27 is shown in cells overexpressing MITOSTATIN (a). Conversely, an increased level of Hsp27 is
observed in cells with lower expression of MITOSTATIN (b, right panel). A total of 5637 bladder cancer cells do not express Hsp27
(b). (c) Growth curves show signiﬁcant decrease in cells overexpressing MITOSTATIN when compared with parental cells and cells
transfected with the MITOSTATIN-antisense plasmid. Data show the mean of three independent experiments±s.e.m. *Po0.05,
**Po0.01.

stage (P ¼ 0.003) (Figure 8c) and higher pT (P ¼ 0.003).
By multivariate analysis, the same variables were
independently associated with MITOSTATIN immunohistochemical levels (stage P ¼ 0.005; pT P ¼ 0.004).

Approximately 23% (11 of 48) of the breast tumors did
not express MITOSTATIN. In the univariate analysis, a
decreased MITOSTATIN immunohistochemical score
correlated to advanced tumor stage (P ¼ 0.047)
Oncogene
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Figure 7 MITOSTATIN overexpression increases staurosporine-induced apoptosis in prostate and bladder cancer cells. (a) TUNEL
(terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling) analysis of cells after 4 h of treatment with 1 mM
staurosporine show a signiﬁcant increase in apoptosis in cells overexpressing MITOSTATIN. The upper panel, representative images
from three independent experiments; bars in the lower panel, s.e.m. *Po0.05, **Po0.01. (b) FACS analysis of LNCaP wild type,
LNCaP control vector V5 and LNCaP B3A cells after 1 and 4 h of treatment with 1 mM staurosporine. Numbers indicate the percentage
of apoptotic cells in each group. (c) MITOSTATIN inhibits Hsp27 activation and affects Hsp27 expression levels. Expression levels of
the protein tested in comparison of the levels observed in the parental cells in three different experiments are shown under the blots.

(Figure 8c), and higher pT (P ¼ 0.027). In breast tumors,
lower MITOSTATIN immunohistochemical expression
was also associated, although not with statistical
signiﬁcance, with presence of lymph node metastases
(P ¼ 0.053). There was no statistically signiﬁcant association between MITOSTATIN expression and estrogen
receptor and progesterone receptor status, histologic
and nuclear grade, and tumor histotype (data not
shown). No other clinical-pathological parameters
Oncogene

resulted independently associated with MITOSTATIN
expression in breast cancers in the multivariate analysis.

Discussion
Previous reports of allelic loss at chromosome 12q24 in
solid tumors have identiﬁed frequencies ranging from 25
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Figure 8 MITOSTATIN is deleted in cancer, mutated in cancer cell lines and its expression is decreased in advanced tumor stages. (a)
MITOSTATIN ORF was not detected by reverse transcription–PCR in three primary prostate tumors (PC), two colon
adenocarcinoma (CC) and one carcinoma of the vulva (VU). In the three prostate samples we also studied the normal counterpart
in which the gene was normally expressed. (b) Examples of immunohistochemical detection of MITOSTATIN in human breast and
bladder. MITOSTATIN cytoplasmatic staining was observed in normal breast (upper left panel) and bladder (upper right panel)
human specimens. Normal mammary glands show a very intense MITOSTATIN staining in both cytoplasm and cellular membrane
(upper left panel). Examples of MITOSTATIN-positive breast (middle left panel) and bladder (middle right panel) cancers and
negative breast (lower left panel) and bladder (lower right panel) tumors (  400). (c) MITOSTATIN immunohistochemical expression
is decreased in advanced stages in breast and prostate. The distribution of the immunohistochemical scores in the different tumor
stages is shown. Original magniﬁcations  10,  20 and  40.

to 55% depending on marker sets used for LOH studies
(Field et al., 1995; Shiseki et al., 1996; Schmutte et al.,
1997; Tirkkonen et al., 1997; Jiang et al., 1998; Kimura
et al., 1998; Koo et al., 1999; Rijken et al., 1999; Sattler
et al., 1999; Aubele et al., 2000). Interestingly, a
restriction fragment length polymorphism study showed
that deletions at 12q24 were more frequent in brain
metastases (68% of LOH) of lung cancers than in stage I
lung tumors (29–33% of LOH). In accordance with this
report, a comparative genomic hybridization analysis on
two microdissected breast carcinomas showed ampliﬁcation of the central portion of chromosome 12 in the
primary tumors and LOH at 12q24 in one metastatic
lymph-node (Aubele et al., 1999). We have previously

suggested that thymine-DNA glycosylase (TDG), an
enzyme initiating T:G mismatch repair by speciﬁcally
excising T from those mismatches through a glysosylase
mechanism in C-T transitions, may be a good tumor
suppressor candidate for 12q24 deletions. To test our
hypothesis, we ﬁrst characterized the structure of the
TDG gene and selected 10 out of 24 (42%) gastric
carcinomas with LOH at the TDG locus. Nevertheless,
although gastric cancer presents a high percentage of
C-T transitions, we found no mutations within the
coding sequence of the remaining TDG allele in the
gastric samples that displayed LOH (Schmutte et al.,
1997). According to these results, we suggested that a
gene different than TDG is the target of 12q24 deletions.
Oncogene
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In this study, we describe the identiﬁcation and
functional characterization of a novel putative tumor
suppressor gene, MITOSTATIN, at 12q24.1 and show
that MITOSTATIN has many of the hallmarks of a
typical tumor suppressor gene.
First, we show that MITOSTATIN is expressed,
although at different levels, in all the human tissues we
tested and that it colocalizes to the mitochondria,
affecting mitochondria morphology and ultrastructural
organization. Second, we show that MITOSTATIN
signiﬁcantly inhibits colony formation and evokes a
dramatic reduction in the rate of DNA synthesis in
various transformed cell lines. Third, MITOSTATIN
overexpression is proapoptotic. Fourth, there is a direct
correlation between the amount of intracellular MITOSTATIN protein and its biological effects: all
MITOSTATIN-overexpressing cells show a lower
growth rate, whereas cells overexpressing an antisense
MITOSTATIN mRNA grow at a slight higher rate than
parental cells.
A previous report (Nishizawa et al., 2005) indicated
that MITOSTATIN is a cytoplasmic protein that
colocalizes with keratin ﬁlaments and was therefore
named trichoplein. However, although our ﬁndings did
not exclude the interaction with keratins, they clearly
show that MITOSTATIN associates with mitochondria
even if it should be stressed that the association is not
complete, the localization of the protein is on the outer
membrane and that other unidentiﬁed intracellular
structures are stained by anti-MITOSTATIN antibodies. Moreover, fusion to GFP of different fragments of
MITOSTATIN showed that the ﬁrst 111 amino acids
are sufﬁcient for a punctuate distribution that partially
overlaps with mitochondria (VA and LS, unpublished
data). The colocalization of MITOSTATIN with
mitochondria (here) as well as with keratin ﬁlaments
(Nishizawa et al., 2005) could rise the hypothesis that
this protein regulates interaction of the organelle with
the intermediate ﬁlaments, a process which impacts on
movement and subcellular localization of the organelle
(Anesti and Scorrano, 2006). In fact, high levels of
MITOSTATIN are associated with changes in the shape
of the mitochondrial network, with a remarkable
fragmentation and perinuclear clustering. Although the
former depends on the activation of the core ﬁssion
machinery, the latter occurs independently of it, as
substantiated by the lack of inhibition by a dominant
negative Drp1. The clusterization phenotype is
typical of apoptotic cells, as observed in the late
nineties in tumor necrosis factora-treated ﬁbroblasts
(De Vos et al., 1998), as well as of cells overexpressing
hFis1, the mitochondrial receptor for Drp1 (Frieden
et al., 2004). We could rule out not only that in our case
it depended on Drp1, but also that it was an
epiphenomenon of the proapoptotic action of
MITOSTATIN, given the lack of inhibition by the
caspase inhibitor zVAD-fmk. It is possible that the
perinuclear clusterization reﬂects the hijack of mitochondria from microtubules to intermediate ﬁlaments,
which MITOSTATIN can bind to (Nishizawa et al.,
2005).
Oncogene

The mitochondrial localization would also explain its
potential involvement in apoptosis. Mitochondria are
central organelles in the regulation of apoptosis, mainly
by amplifying death signals by the release of cytochrome
c and other protein cofactors from the inter-membrane
space to the cytosol, where they activate effector
caspases. The mechanisms by which increased expression of MITOSTATIN facilitates apoptosis remain to be
resolved, but it is conceivable that this occurs through a
facilitator effect on the mitochondrial pathway of
apoptosis.
In this study, we discover a link between MITOSTATIN expression and Hsp27 phosphorylation. Hsp27 is a
heat-shock protein and in quiescent cells exists predominantly as a large oligomeric unit of B800 kDa.
During stress, the level of Hsp27 and the amount of
phosphorylation on Ser 15, 78 and 82 increases,
resulting in a shift in Hsp27 from an oligomeric unit
to tetrameric and dimeric units (Bruey et al., 2000).
Hsp27 has cytoprotective effects during cellular stress
and operates as a molecular chaperone inhibiting
protein unfolding. Hsp27 also directly interferes with
caspase activation, modulates oxidative stress and
regulates the cytoskeleton scaffolding (Parcellier et al.,
2003). Higher levels of Hsp27 have been correlated with
an increased metastatic potential of tumor cells in vitro
and in vivo as well as an enhanced resistance to therapy
(Kamada et al., 2007). Hsp27 has been frequently
detected overexpressed in human cancer (Love and
King, 1994; Ehrenfried et al., 1995; Langdon et al., 1995;
Takashi et al., 1998; Cornford et al., 2000; Lebret et al.,
2003). Speciﬁcally in prostate cancer, elevated Hsp27
expression has been linked to hormone resistance and
poor outcome (Rocchi et al., 2004, 2005). Thus,
MITOSTATIN-evoked effects on Hsp27 phosphorylation might be directly linked to MITOSTATIN ability
to inhibit cell growth and be proapoptotic during cell
stress.
The loss of tumor suppressor gene regulatory function
represents an important step in malignant progression
(Hanahan and Weinberg, 2000). Mutations of tumor
suppressor genes are considered recessive, and both
copies of these genes must be inactivated before the cell
is at risk of transformation, the so-called ‘two hit’
hypothesis (Knudson, 2000). The heterozygous situation, in which only one allele is not functioning, may
cause a reduced action of the gene (haploinsufﬁciency)
and favors the development of the neoplastic phenotype.
Therefore, after we determined that MITOSTATIN is
localized in a chromosomal region deleted in cancer and
that its expression is induced by decorin, a cancer-cell
growth inhibitor (Iozzo, 1998), we performed a mutational analysis in cell lines and primary human tumors
of different origin. Approximately 6% of the cancer
samples analysed show homozygous deletions of the
MITOSTATIN gene. In three primary human prostate
cancers, we showed that the MITOSTATIN mRNA was
normally expressed in the normal adjacent glands. Three
of the four point mutations present in cancer cell lines
(RF48 gastric carcinoma-derived cell line, prostate cancer
LNCaP cell line and pancreatic carcinoma-derived SU86
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cell line) were detected in one of the two MITOSTATIN
alleles together with the normal allele. MITOSTATIN
was homozygously mutated in the CAPAN1 pancreatic
carcinoma-derived cells. The low incidence of MITOSTATIN mutations suggests that other molecular mechanisms are responsible for the loss of expression of
MITOSTATIN observed in primary tumors. The
presence of mutations in only one of the two alleles
also suggests that MITOSTATIN could also be a
haploinsufﬁcient tumor suppressor.
Several reports have suggested that 12q24 contains a
tumor suppressor gene involved in multiple tumor types
(Field et al., 1995; Shiseki et al., 1996; Schmutte et al.,
1997; Tirkkonen et al., 1997; Jiang et al., 1998; Kimura
et al., 1998; Koo et al., 1999; Rijken et al., 1999; Sattler
et al., 1999; Aubele et al., 2000). We mapped the
MITOSTATIN gene to this region and showed a loss of
MITOSTATIN RNA expression in several carcinomas.
Although, the status of DNA and RNA is important,
the actual determinant of a gene function is its protein
expression. Using immunohistochemistry experiments,
we showed that MITOSTATIN protein is absent or
greatly reduced in 22% of human bladder cancers and
23% of breast adenocarcinomas. Loss of MITOSTATIN expression correlates with advanced disease in both
types of cancer. Furthermore, it was associated with
lymph-node metastases in breast cancer. These in vivo
data represent an additional evidence of the possible
tumor suppressor function of MITOSTATIN.
In conclusion, we have identiﬁed and functionally
characterized MITOSTATIN, a novel putative tumor
suppressor gene localized to the mitochondria. We
further provide the ﬁrst evidence that loss of MITOSTATIN protein expression may play a role in human
tumorigenesis. Thus, loss of function of MITOSTATIN
may interrupt the inhibitory circuit, possibly regulated
by extracellular components, such as decorin, facilitating the growth and spread of neoplastic cells.
Our ﬁndings support the hypothesis that MITOSTATIN behaves as a classical tumor suppressor in solid
tumors. Furthermore, we demonstrate, for the ﬁrst time,
that MITOSTATIN is implicated in the control of cell
growth and apoptosis and that MITOSTATIN protein is
signiﬁcantly decreased or absent in advanced bladder and
breast cancers. It remains to be determined how
MITOSTATIN functions in mitochondrial homeostasis
as well as how a mitochondrial protein acts as tumor
suppressor. Additional functional studies are needed to
clarify the role of this protein in neoplastic transformation, and the mechanisms of MITOSTATIN inactivation.

2000 from archives of the Pathology Department of Thomas
Jefferson University. Samples studied included 31 bladder, 23
colon-rectum, 20 prostate, 13 ovary, 13 vulva and 2 cervical
cancers. All samples were obtained from patients who gave
informed consent to use excess pathological specimens for
research purposes. The AccuMax Array-A215 (ISU ABXIS
Co., Seoul, South Korea) including ninety-four 0.6-mm
bladder cancer cores was utilized for the immunohistochemistry. Forty-eight invasive breast carcinomas (41 ductal and 7
lobular) were selected from the Pathology Tissue Bank of
Thomas Jefferson University and used to develop a tissue
microarray based upon the appropriate IRB-approved protocol. Adjacent normal breast from four diseased patients was
also included.
Cell proliferation, colony formation assays and subcellular
fractionation
Cells were plated in triplicate in a six-well tissue culture plate.
Proliferation was assessed by counting the cells daily for 4
days, and the mean values of three independent experiments
were analysed. Colony forming assay was performed on cells
plated at a density of 400 cells per 100 mm dish. On day 15,
cells were ﬁxed with phosphate-buffered saline–3.7% formaldehyde and stained with crystal violet for colony counting.
Separation of crude organelle fractions was performed on cell
using the differential centrifugation methods (Bourgeron et al.,
1992; Peruzzi et al., 1999) with minor modiﬁcations.
Generation of MITOSTATIN polyclonal antibody
and immunological analyses
The anti-MITOSTATIN antibody was raised in rabbit against
glutathione 6HIS-fusion MITOSTATIN protein corresponding to nucleotides 816–1712, which was expressed in Escherichia coli and puriﬁed with a fusion tag column. Protein
extraction and immunoblot analyses were carried out as
described previously (Vecchione et al., 2002). Anti-MITOSTATIN (1:1000), anti-actin (1:10 000; Sigma, St. Louis, MO,
USA), anti-FLAG (1:1000; Sigma), anti-cytochrome c (1:1000;
Cell Signaling, Beverly, MA, USA), anti-caspase-3 (1:1000;
BD Pharmingen Inc., San Diego, CA, USA), anti-PARP
(1:1000; BD Pharmingen Inc.), anti-HSP27 (1:1000; Cell
Signaling), anti-p38 MAP kinase (1:1000) and the phosphorylated anti-phospho-HSP27 ser82 (1:1000), anti-phosphoHSP27 ser78 (1:1000) and anti-phospho-p38 MAPK thr180/
tyr182 (1:1000) were used as primary antibodies. Immunoﬂuorescence experiments were carried out on ﬁxed cells as
described before (Monami et al., 2006).

Materials
Additional details of materials are provided in Supplementary
Information.

Immunohistochemistry
In this study, we used the immunohistochemistry procedure
described previously (Vecchione et al., 2002) with minor
modiﬁcations. Sections were immunostained overnight at
room temperature with a 1:100 dilution of the anti-MITOSTATIN antibody. The primary antibody was omitted and
replaced with pre-immune serum in the negative control. All
sections were examined independently by two investigators
(RB, JPP), and complete agreement was reached for MITOSTATIN positivity and negativity. Positive staining of antiMITOSTATIN antibody was semiquantiﬁed with a four-tier
system: þ þ þ , 67–100% MITOSTATIN-positive cells;
þ þ , 34–66% MITOSTATIN-positive cells; þ , 5–33%
MITOSTATIN-positive cells; and 0, the tumors in which
>95% of cells did not express MITOSTATIN.

Tissue samples
A total of 102 (26 matched normal and tumor tissues) deidentiﬁed frozen primary tumors were collected from 1994 to

Statistical analysis
Statistical analysis was carried out with SigmaStat for
Windows version 3.10 (Systat Software). All values were

Materials and methods

Oncogene

MITOSTATIN is downregulated in human cancer
A Vecchione et al

268
expressed as mean±s.e. Differences between means were
evaluated with double-sided Z-test. The w2 test was used to
examine the categorical variables and the association between
MITOSTATIN immunohistochemical expression levels and
other clinicopathological variables in univariate analysis. To
identify variables independently associated with MITOSTATIN
immunohistochemical levels, backward selection multivariate
analysis was performed using the logistic regression model.
Differences were considered statistically signiﬁcant at Po0.05.
Abbreviations
GFP, green ﬂuorescent protein; LOH, loss of heterozygosity.
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